05/19/22 2:00 PMNasdaq : BWV low floatBlue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine CandidateBlue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (“CeRDI”), an initiative of InstitutoRHEA-AIvery positive
05/13/22 5:01 PMNasdaq : BWV earningslow floatBlue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business DevelopmentsClosed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 million Multiple vaccine candidate developments, including additional data for universal influenza candidate, BWV-101, identifyingRHEA-AIneutral
05/12/22 8:30 AMNasdaq : BWV conferenceslow floatBlue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment ConferenceBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer ofRHEA-AIneutral
05/11/22 1:00 PMNasdaq : BWV low floatBlue Water Vaccines Announces Expanded License Agreement with St. Jude Children’s Research Hospital for Novel Bacterial Vaccine PlatformBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today announced an expanded license agreement has been signed with St. Jude Children’s Research Hospital (“St.RHEA-AIneutral
04/21/22 8:45 AMNasdaq : BWV low floatBlue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DCBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today issued the below statement regarding its Form 8-K filed with the Securities and Exchange CommissionRHEA-AIneutral
04/20/22 9:25 AMNasdaq : BWV low floatBlue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq RulesBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant globalRHEA-AIneutral
04/18/22 7:30 AMAMEX, Nasdaq : OGEN, BWV, CRXT conferencesOragenics to Participate at the World Vaccine Congress Washington 2022Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including coronavirus, today announced that Kimberly Murphy, a member of the Company’ s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’ s lead product, NT-CoV2-1, an intranasal vaccine candidate,...RHEA-AIneutral
04/13/22 9:30 AMNasdaq : BWV low floatBlue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq RulesBlue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant globalRHEA-AIneutral
04/11/22 9:56 AMNasdaq : BWV conferenceslow floatBlue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) aRHEA-AIneutral
03/22/22 7:00 AMNasdaq : BWV low floatBlue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform VersatilityBlue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform. The data supports BWV’s ongoing development of a transformational universal influenza vaccine, as well as a rotavirus & norovirus vaccineRHEA-AIneutral